Background {#Sec1}
==========

Practice-based randomised controlled trials (RCTs) in primary care are essential, as they provide the basis for evidence-based decision-making in a central sector of health care \[[@CR1]\]. Furthermore, being considered the gold standard for clinical research, high-quality RCTs led by general practitioners (GPs) are of crucial importance to enhance the still limited acceptance of general practice/family medicine as an academic discipline at German universities \[[@CR2]\]. In recent years, several countries, such as the United Kingdom, the United States and the Netherlands, have invested greatly in the establishment of an efficient primary care research infrastructure (university departments of general practice or family medicine and practice networks) and the in practice-based RCTs \[[@CR3]--[@CR5]\].

Although Germany is Europe's most populous country, its output of primary care research medicine lags far behind that of the United Kingdom and the Netherlands \[[@CR3]\]. In 2000 only 5 of 36 German medical schools had a chair of general practice or family medicine, and by 2006 family medicine institutes or divisions had been established at 13 German universities \[[@CR6]\]. By summer 2015, chairs had been established at 25 of 37 medical schools. Recently, a group of researchers from German academic departments of general practice published an analysis of obstacles in clinical trials \[[@CR5]\]. In Germany, laboratory research is regarded more highly than clinical research. The single national funding programme for clinical research is highly competitive and specialist-dominated, and it usually favours innovation rather than comparative effectiveness research. General practice as an academic discipline is still not fully implemented, and most of the existing institutes are small. German GPs work in a market-oriented competitive system, mostly in small practices with a high caseload. Sustained funding for research-oriented practice networks is almost inexistent \[[@CR5]\]. Despite these difficult circumstances, researchers in German university departments of general practice or family medicine have performed a number of randomised trials in recent years. Our aim in this article is to provide a descriptive overview of the current status of research productivity by performing a systematic review of the amount, topics, methods, quality and findings of randomised trials carried out by German university departments of general practice.

Methods {#Sec2}
=======

The aims and basic methods we used to search the literature, establish the selection criteria and process, extract data, and assess risk of bias were predefined in an unpublished protocol (in German).

Literature search {#Sec3}
-----------------

Publications were identified (1) by searching the Scopus database (<http://info.scopus.com/>; last searched 22 Apr 2015); (2) by screening publication lists of existing departments, institutes and divisions of general practice or family medicine at German medical schools; and (3) by tracking potentially relevant references in already-included articles. We selected Scopus as a database for electronic searching as it comprises PubMed/MEDLINE and also covers European journals in languages other than English, which are rarely listed in PubMed/MEDLINE. The following algorithm was used for our Scopus database search: AFFILCOUNTRY (deutschland) OR AFFILCOUNTRY (germany) AND AFFILORG (allgemeinmedizin) OR AFFILORG (general practice) AND PUBYEAR \> 2009 AND PUBYEAR \< 2015 AND (Random\* OR Cluster). Publication lists were obtained directly from the departments, institutes and division and/or from their websites. Articles published until 2010 had been originally searched and identified for a previous review on any original research publication done by researchers at German academic family medicine departments \[[@CR7], [@CR8]\]. Articles published between 2011 and 2014 were identified by updated searches. (The year 2010 was also searched to detect trials potentially added to Scopus after completion of the search for our previous work.)

Study selection {#Sec4}
---------------

We included randomised (individual- or cluster-level) controlled trials published between January 2000 and December 2014 in which the first or last author of at least one relevant publication (study protocol and/or a publication reporting trial results) was affiliated with a general practice or family medicine department, institute or division of a German medical school. (For simplicity, only the term *department* is used in the rest of this article.) Within the overall project, we also collected published study protocols of RCTs for which results were not yet available by the end of 2014, but these are not included in the systematic review presented here. There were no predefined further exclusion criteria.

One reviewer screened titles and (to the extent available) abstracts of all Scopus search hits and excluded all clearly irrelevant publications. The full text was obtained for all remaining articles. For our previous review project \[[@CR7]\], these were any articles potentially reporting original data. All articles actually reporting original data were then analysed for study topic and bibliographical and methodological characteristics. For our present analyses, only articles reporting on a prospective clinical trial with a control group or a protocol of such a study were considered as potentially relevant and checked as full texts. Titles and abstracts identified by our updated searches (2010--2014) were screened for randomised trials; publications clearly not reporting or related to a randomised trial were excluded. The first author checked all full texts obtained formally for compliance with our selection criteria. In cases of uncertainties, the senior author also read and assessed the articles.

Data extraction {#Sec5}
---------------

One reviewer extracted the following information (apart from reference information included in the Endnote file) from all included studies: study question in participants, intervention, control, outcome format; in case of a disease focus, the condition was recorded according to coding in the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, and the International Classification of Primary Care, Second Edition (<http://www.who.int/classifications/icd/adaptations/icpc2/en/>); information on authors; type and number of participating practices; the number of patients included, analysed and completing the studies, as well as information on recruitment; funding; study design issues, including duration, randomisation, blinding, sample size calculation and analysis; relevant outcome measures; and definition of a primary outcome measure.

Assessment of risk of bias {#Sec6}
--------------------------

Risk of bias was assessed using the risk of bias assessment tool of the Cochrane Collaboration \[[@CR9]\] with items on random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. Assessment was performed on the basis of the instructions given in the Cochrane Handbook \[[@CR9]\] with a 'rule book' further standardising procedures, taking into account the great clinical and methodological diversity of the trials included in our review. Assessments were done by the first author. About half of the assessments were checked again by the senior author.

Summarising the results of included trials {#Sec7}
------------------------------------------

To provide a crude overview of the results of the included trials, we used both vote count methods and effect size calculations. For the vote count, the first author categorised overall study findings as 'positive' (findings in the intervention group consistently and statistically significantly better than in the control group), 'trend positive' (significant differences in favour of the intervention group only for some outcomes), 'no difference', 'trend negative' and 'negative' (as 'trend positive' and 'positive' but favouring the control group). Two vote counts were done: one based on what study authors reported and concluded and one according to the reviewer's perception.

In addition, we calculated effect size estimates for predefined main outcome measures or, if a main outcome measure was not clearly defined, for the outcome we considered most relevant. Raw data in four formats (means, standard deviations and sample sizes; mean differences, samples sizes and *p* values or confidence intervals; events and number of participants per group; odds ratios and confidence intervals) were entered into a Comprehensive Meta-Analysis 3.3 spreadsheet (<http://www.meta-analysis.com/index.php>). This software allows conversion of different types of raw data into standardised mean differences (with 95 % confidence intervals). Positive values indicate better outcomes in the intervention group. We considered standardised mean differences ≤0.4 as small effects, between 0.41 and 0.7 as moderate effects and \>0.7 as large effects \[[@CR10]\].

Results {#Sec8}
=======

In our literature searches, we identified a total of 2228 references published between January 2000 and December 2014 (Fig. [1](#Fig1){ref-type="fig"}). On the basis of our review of titles and abstracts or the full-text check of articles which had already been identified for our previous review \[[@CR7]\], a total of 2005 references were excluded as clearly irrelevant. Altogether, full texts of 223 publications were obtained. Of these, 128 were excluded because neither the first nor the last author was associated with a GP department, the studies were not randomised trials, or the authors reported additional information related to a randomised trial included which was not directly related to the main results (e.g., accompanying qualitative studies or cross-sectional analyses of baseline data). We extracted basic information on 60 studies described in 95 publications. Twenty-seven studies in 33 publication were excluded from the review (see Additional file [1](#MOESM1){ref-type="media"} for references and Additional file [2](#MOESM2){ref-type="media"} for study characteristics). For 17 trials, protocols (17 publications) were published between 2008 and 2014, but results were not available at the end of 2014. We decided post hoc to exclude a further 10 trials (16 publications) from the analyses for the present article because we considered them irrelevant to the primary aim of our overview. These studies comprised four trials, all comparing acupuncture with a sham acupuncture control having a first author with an affiliation with an institute of family medicine or general practice at the time of the publication for which we had definite information that the studies had actually been planned and performed when the author had worked at other departments; five which were short-term experimental trials focussed on physiological measures (e.g., effects of suggestion on pupil size) without any direct relation to the practice of family medicine; and one trial with a last author with an affiliation with a German institute of general practice but in which the study was performed exclusively in the United States.Fig. 1Flowchart of the study process

Thirty-three trials (sixty-two publications) were included in the final analysis (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}; see Additional file [1](#MOESM1){ref-type="media"} for references). The number of trials increased sharply over time from 2 trials published between 2000 and 2004 to 10 trials published between 2005 and 2009 and 21 trials published between 2010 and 2014. Fifteen trials were funded by federal or regional ministries of education or health, eight trials received funding from a variety of other non-industry resources (e.g., foundations, social health insurance), two were industry-sponsored, and for eight the source of funding was not reported. We categorised 17 studies as cluster-randomised trials (trials in which the unit of randomisation and the level on which the outcome was measured differed; e.g., randomisation of practices and outcome measurement on the level of individual patients) and 16 trials as 'normal' randomised trials (randomisation of individuals with outcome measurement in the same individuals).Table 1Characteristics of included studies - cluster-randomised trials (*n* = 17)First author, yearParticipants' conditionsInterventionsControlsMain outcomesUnit random.Sample size^a^Altiner, 2007CoughEducational intervention (GPs and patients)No interventionAntibiotic prescribingPhysician104/2787Becker, 2010Low back painGroup 1: Multifaceted guideline interventionPostal dissemination of the guidelineFunctional capacityPractice118/1378Group 2: 1 + training of practice nursesErler, 2012Elderly with chronic kidney diseaseMultifaceted intervention helping adequate drug dosingUsual carePrescription exceeding recommended doses \>30 %Practice46/404Freiberger, 2013Community-dwelling elderlyRisk of falls prevention programNo interventionRisk of falling (main outcome falls not yet available)Practice33/378Gensichen, 2009DepressionCase management (communication, monitoring, behavioural activation)Usual careDepressive symptomsPractice74/626Junius-Walker, 2012Elderly GP patientsTraining on structured priority-setting consultationNo trainingDoctor-patient agreement on prioritiesPractice42/347Kaufmann-Kolle, 2011Asthma bronchialeQuality circles with open benchmarkTraditional anonymous feedback in quality circlesInappropriate drug combinations, asthma severityQuality circle6/unclearKrones, 2008All undergoing cholesterol measurementCommunication/shared decision-making in cardiovascular risk patientsTraining on other subjectsPatient satisfaction, risk scores, participationCME groups14/1132Mehring, 2013Individuals with BMI ≥25 kg/m^2^Web-based weight reduction programUsual careWeight reduction at 12 weeksPractice92/186Mehring, 2014Individuals willing to stop smokingWeb-based weight reduction programUsual careBiochemically confirmed smoking status at 12 weeksPractice92/168Peters-Klimm, 2009Chronic heart failureMultifaceted, interdisciplinary medical educational interventionSingle 3-h lectureQuality of lifePractice37/168Rosemann, 2007OsteoarthritisGroup 1: Case management training GPsNo interventionQuality of life (Arthritis Impact Measurement Scales Short Form)Physician75/1125Group 2: 1 + courses also for nursesSzecsenyi, 2012Type 2 diabetesIdeally implemented disease managementUsual disease management careAchievement of target values for HbA1c and blood pressurePractice177/7807Tinsel, 2013HypertensionShared decision-making trainingNo training (usual care)Patients' perceived participation, blood pressurePractice37/1120Vollmar, 2007DementiaTraining in evidence-based dementia treatment (two slightly different groups)Basic information (usual care)Time to nursing home placement, deathPractice303/390Vollmar, 2010GPsBlended learning intervention on dementia careLecture and case discussionKnowledge gainQuality circle26/305Vormfelde, 2014Patients receiving oral anticoagulation therapyEducational program for patients provided by practice nursesBrochure onlyKnowledge, feelings about safety, complicationsPractice22/345*Unit random.* unit of randomisation, *GP* general practitioner, *CME* continuing medical education, *HbA1c* haemoglobin A1c, BMI body mass indexSee Additional file [1](#MOESM1){ref-type="media"} for references^a^For cluster-randomised trials, first number of clusters randomised/number of patientsTable 2Characteristics of included studies: 'normal' randomised trials (*n* = 16)First author, yearParticipants/conditionsInterventionsControlsMain outcomesUnit random.Sample sizeRandomised trials investigating specific treatments (*n* = 11) Bleidorn, 2010Uncomplicated urinary tract infectionIbuprofenCiprofloxacinSymptom resolution at day 4Patient80 Bücker, 2010Acute, uncomplicated back painHanding out evidence-based back pain leafletNon-specific informationFunctional capacity (Hannover Functional Ability Questionnaire)Patient189 du Moulin, 2009COPDHome-based exercise trainingNo intervention6-minute walk test, quality of life, lung functionPatient20 Frese, 2012GP patients older than 70 years of ageComprehensive geriatric assessmentUsual careMortality, nursing home admissionPatient1620 Gastpar, 2003Neurotic anxietyKava special extract WS 1490PlaceboAnxiety Status InventoryPatient141 Hensler, 2009Common coldIntramuscular autologous blood therapyPlaceboDuration of coldPatient139 Jobst, 2005Recurrent respiratory infectionsIntramuscular autologous blood injectionHomeopathic complex remedy (Engystol®; Biologische Heilmittel Heel, Baden-Baden, Germany)Sick daysPatient80 Klein, 2013Non-specific neck painStrain-counterstrain (osteopathic technique)Sham interventionRange of motion and pain intensityPatient61 Peters-Klimm, 2010Chronic heart failureCase management (telephone monitoring and home visits)Usual careQuality of life, Kansas City Cardiomyopathy QuestionnairePatient199 Schencking, 2013Osteoarthritis (hip or knee)Group 1: Kneipp hydrotherapyBothPain intensity, quality of life, mobilityPatient30Group 2: Conventional physiotherapy Voigt, 2011MigraineOsteopathic manipulative treatmentNo interventionMigraine Disability Assessment (MIDAS), quality of life, painPatient42Randomised trials on other topics (*n* = 5) Bergold, 2013First-year residentsOnline course in evidence-based medicineWait listKnowledge gainFirst-year resident120 Blank, 2013Medical studentsAdditional near-peer teaching for physical examinationEstablished curricular course onlyObjective structured clinical examinationMedical student84 Butzlaff, 2004General practitionersAccess to computerized guidelinesNo specific accessKnowledge gainPhysician72 Hoffmann, 2014Physicians and nurses of GP practicesTeam-based patient safety culture assessment and interventionShort, facultative seminar on error managementError managementPractice65 Müller-Bühl, 2011Adult GP patientsAnswering three questions before completing the SF-36 quality of life questionnaireCompleting the SF-36 as usualNumber of missing itemsPatient215*COPD* chronic obstructive pulmonary disease, *GP* general practitioner, *SF-36* 36-item Short Form Health Survey, *Unit random.* unit of randomisationSee Additional file [1](#MOESM1){ref-type="media"} for references

Cluster-randomised trials {#Sec9}
-------------------------

The 17 cluster-randomised trials had a total of 37 study arms (14 two-armed and 3 three-armed trials; Table [2](#Tab2){ref-type="table"}). Units of randomisation were quality circles or continuing medical education groups of several physicians in 3 studies, practices in 12 studies and individual physicians in 2 studies. Outcomes were measured on the level of individual patients in all but one study, in which the outcome was measured on the level of physicians. The number of randomised clusters varied between 6 and 303, and the number of included patients (physicians in 1 study) ranged between 168 and 7807. The conditions or clinical problems and outcomes assessed varied widely; no specific subject was investigated in more than one study. The majority of interventions were focused on the improvement of processes (managed care, more efficient or evidence-based strategies, better communication), and only a few were focused on defined, specific treatment strategies (e.g., a weight reduction program or a fall prevention intervention for the elderly). Control interventions were no intervention/usual care or minimal interventions unlikely to have relevant effects.

Many cluster-randomised trials were logistically complex and associated with high risk of bias (Table [3](#Tab3){ref-type="table"}). While the generation of the random sequence was either adequate (ten studies) or not reported (seven studies), we considered the risk of selection bias related to allocation concealment high in ten studies, unclear in a further two and low in only five. The allocation of clusters was mostly concealed adequately. However, in those ten studies which received a high-risk rating, patients were explicitly or probably recruited *after* the practices knew their allocation status. Most authors seem to have been aware of this problem but were unable to manage recruitment otherwise. While in some trials this did not result in obvious imbalances, in others the number of patients recruited in the intervention and control groups differed beyond chance or there were clinically relevant differences in baseline characteristics of patients. Given the nature of the interventions tested, blinding of practices and individuals was not possible in any trial. While outcomes measured were partly objective, performance bias on the level of co-interventions cannot be ruled out. In five trials, a relevant proportion of randomised clusters did not recruit any patients and/or had a high percentage of incomplete outcome data, which resulted in a high risk of attrition bias. We considered the risk of major bias on the level of reporting outcomes to be low based on our (liberal) operationalization of this item. In summary, each of the cluster-randomised trials had a high risk of bias for at least one item.Table 3Risk of biasFirst author, yearSequence generationAllocation concealmentBlinding of participantsBlinding of outcome assessmentIncomplete outcome dataSelective reportingCluster-randomised trials Altiner, 2007LowHighHighLowHighLow Becker, 2010LowHighHighHighHighLow Erler, 2012LowLowHighLowLowLow Freiberger, 2013LowHighHighHighUnclearLow Gensichen, 2009LowHighHighHighLowLow Junius-Walker, 2012UnclearHighHighHighUnclearLow Kaufmann-Kolle, 2011UnclearHighHighUnclearHighLow Krones, 2008UnclearHighHighHighUnclearLow Peters-Klimm, 2009LowLowHighLowUnclearLow Mehring, 2013LowHighHighLowUnclearLow Mehring, 2014LowHighHighLowUnclearLow Rosemann, 2007UnclearLowHighHighUnclearLow Szecsenyi, 2012UnclearUnclearHighLowLowLow Tinsel, 2013LowLowUnclearUnclearHighLow Vollmar, 2007UnclearHighHighLowLowLow Vollmar, 2010UnclearLowHighUnclearHighLow Vormfelde, 2014LowUnclearHighHighUnclearLowRandomised trials investigating specific treatments Bleidorn, 2010LowLowLowLowLowLow Bücker, 2010LowLowHighHighHighLow du Moulin, 2009LowLowHighLowUnclearLow Frese, 2012UnclearUnclearLowLowHighLow Gastpar, 2003LowLowLowLowLowUnclear Hensler, 2009UnclearLowLowLowUnclearLow Jobst, 2005LowLowHighHighUnclearLow Klein, 2013LowLowHighLowLowLow Peters-Klimm, 2010LowLowHighHighUnclearHigh Schencking, 2013LowLowHighHighLowUnclear Voigt, 2011UnclearUnclearHighHighLowHighRandomised trials on other topics Bergold, 2013LowLowHighHighLowLow Blank, 2013LowLowHighLowHighLow Butzlaff, 2004LowUnclearHighHighLowLow Hoffmann, 2014UnclearUnclearHighLowLowLow Müller-Bühl, 2011UnclearUnclearUnclearUnclearLowLowSee Additional file [1](#MOESM1){ref-type="media"} for references

In the vote count, the conclusions of authors were categorised as 'positive' for five trials, as 'trend positive' in three and as 'no difference' in nine trials. The vote count based on the reviewer's conclusion yielded similar categorisations (four, three and ten trials, respectively). Effect sizes estimates could be calculated for 15 trials with 18 comparisons of an intervention with a control group (Table [4](#Tab4){ref-type="table"}). Only two trials had moderately large group differences, with standardised mean differences of −0.60 and −0.63, respectively. In all other trials, differences were small, ranging from −0.30 to 0.17. Confidence intervals did not include zero in eight trials.Table 4Effect size estimatesFirst author, yearOutcome used for effect size estimationSMDLLULCluster-randomised trials Altiner, 2007Frequency of antibiotic prescription0.300.140.46 Becker, 2010Functional capacity 6 (group 1 vs. controls)0.150.010.29 Becker, 2010Functional capacity 6 (group 2 vs. controls)0.11−0.030.25 Erler, 2012Number of patients with inadequate prescriptions0.23−0.110.56 Gensichen, 2009Depression scores0.220.050.38 Krones, 2008Patient participation and satisfaction score0.230.100.35 Peters-Klimm, 2009Quality of life physical function−0.17−0.500.16 Rosemann, 2007Arthritis impact, lower body (group 1 vs. controls)0.08−0.090.25 Rosemann, 2007Arthritis impact, lower body (group 2 vs. controls)0.170.000.34 Szecsenyi, 2012Number of patients reaching treatment targets0.01−0.040.07 Tinsel, 2013Shared decision-making score0.07−0.060.20 Vollmar, 2007Institutionalisation (group 1 vs. controls)0.08−0.240.41 Vollmar, 2007Institutionalisation (group 2 vs. controls)−0.07−0.380.25 Vormfelde, 2014Knowledge scores anticoagulant treatment0.630.410.85 Freiberger, 2013Mobility0.270.050.49 Mehring, 2013Weight reduction0.600.270.92 Mehring, 2014Smoking cessation0.08−0.610.77 Vollmar, 2010Knowledge gain0.02−0.280.33Randomised trials investigating specific treatments Bücker, 2010Functional capacity0.28−0.100.66 Peters-Klimm, 2010Quality of life physical functioning−0.04−0.380.31 Bleidorn, 2010^a^No symptom resolution0.15−0.370.68 du Moulin, 20096-minute walk test1.030.101.97 Frese, 2012Death0.140.050.22 Gastpar, 2003Anxiety scores0.15−0.180.48 Hensler, 2009Illness duration0.05−0.320.41 Jobst, 2005^a^Illness days0.02−0.420.46 Klein, 2013Mobility restriction, neck0.24−0.270.74 Schencking, 2013Pain (group 1 vs. controls)0.20−0.681.08 Schencking, 2013Pain (group 2 vs. controls)0.10−0.780.97Randomised trials on other topics Bergold, 2013Knowledge of EBM0.760.381.14 Blank, 2013Score for clinical examination quality1.160.581.74 Butzlaff, 2004Knowledge gain0.11−0.430.65 Hoffmann, 2014Error management−0.06−0.570.45 Müller-Bühl, 2011Number of missing items0.25−0.020.52*SMD* standardised mean difference, *LL* lower limit of the 95 % confidence interval, *UL* upper limit of the 95 % confidence interval^a^Studies comparing two active treatments (equivalence or non-inferiority trials)Data are presented as standardised mean differences with 95 % confidence intervals. Negative values indicate better outcomes in the intervention group.See Additional file [1](#MOESM1){ref-type="media"} for references

'Normal' randomised trials {#Sec10}
--------------------------

In a total of 16 trials with 33 study arms (one 3-armed trial), the unit of randomisation and the level of outcome measurement were the same (Table [2](#Tab2){ref-type="table"}). In 11 trials, researchers investigated the effectiveness of specific clinical interventions; these interventions were allocated to individual patients. Conditions as well as experimental and control interventions investigated were highly variable. Six of the eleven trials investigated complementary or alternative treatments (e.g., herbal drugs, autologous blood therapy, osteopathy or hydrotherapy). Sample sizes varied between 20 and 1620 patients. In the five remaining trials, researchers investigated educational interventions (three trials), the impact of access to computerized guidelines (one trial) and a methodological issue relevant to quality of life measurement in heterogeneous GP patient populations (one trial). The unit of randomisation was variable. Sample sizes varied between 72 and 215 participants.

In general, 'normal' randomised trials were logistically and methodologically less challenging than cluster-randomised trials. While not all trials reported details on sequence generation and allocation concealment, the risk of bias was never considered high. Instead, the risk of performance and measurement bias was considered high in the majority of studies due to the lack of blinding and/or use of subjective outcomes. Risk of bias due to incomplete outcome data was highly variable due to differences in challenges (some short-term studies did not have any attrition and had no or little missing data) and reporting or handling of the problems experienced. In two trials, there was clear evidence of biased reporting, either by selecting outcomes or by reporting inadequate analyses (focus on changes and inference testing within groups).

The authors' conclusions were 'positive' in four trials, 'trend positive' in six and 'no difference' in six trials (reviewer's conclusion three trials 'positive', five trials 'trend positive' and eight trials 'no difference'). Standardised mean differences could be calculated for 15 trials including 16 comparisons (Table [4](#Tab4){ref-type="table"}, lower part). Two trials actually compared active treatments. Large differences were reported in two trials and moderately large differences in one trial. In all other trials, point estimates of standardised mean differences were \<0.3.

Discussion {#Sec11}
==========

Despite limited funding, German university institutes for general practice or family medicine increasingly perform randomised trials; yet, the total number of 33 trials relevant to primary care published in a period of 15 years seems modest. In cluster-randomised trials, we noticed an emphasis on interventions aimed at improving processes in practices, while trials on drugs were very rare. The methodological quality of the trials was variable, with frequent relevant problems related to allocation concealment in cluster-randomised trials. Effects of the tested interventions over usual care or minimal interventions were mostly small.

It is somewhat difficult to compare the RCT output of university departments for general practice in Germany with that of other countries, as there is very limited information on such output internationally. The only systematic analysis limited to 'RCTs with a general practice setting' we found in the literature was published by Kortekaas et al. in 2012 \[[@CR2]\]. These authors searched MEDLINE using the text words and/or MeSH ('medical subject headings') terms 'general practice', 'primary healthcare' or 'family medicine' to identify relevant trials published between 1990 and 2010. The 1935 publications on RCTs included 549 originated from the United States, 511 from the United Kingdom, 201 from Scandinavia, 194 from the Netherlands and 480 from a variety of other countries. The number of trials originating from Germany was not reported in the published review, but the first author kindly provided us an unpublished list of the 52 German studies. Of the 38 publications included by Kortekaas et al. that were published between 2000 and 2010, 8 were also included by us (while we identified additional 9 trials for this period), 3 were relevant protocol publications without results (also identified by us but excluded from the analysis presented), 1 was an additional publication on a trial already included in both reviews, 1 turned out not to be a randomised trial and 1 publication was a duplicate. The remaining 24 publications were not included by us because in 22 not a single author was affiliated with a GP department (or at least reported a private general practice as contact) and in 2 only a middle author had a GP department affiliation. This comparison shows that, depending on the objective and the methods used, bibliometric analyses can produce quite different findings. Yet, it makes clear that, compared with countries leading in primary care research (UK, USA, Netherlands, Scandinavian countries), Germany's output of RCTs in the area of academic family medicine is rather low, and that many 'primary care trials' in Germany are conducted *with* or *on* GPs rather than *by* GPs.

There is a remarkable focus by German GP institutes on process-oriented cluster-randomised trials. Also, among the 16 protocols of trials without published results by 2014 identified by our search, 12 described cluster-randomised trials (see Additional file [2](#MOESM2){ref-type="media"}). This focus seems well compatible with the priorities in the research agenda of the European General Practice Research Network that ask for RCTs 'which take into account broad issues such as patient preferences, multimorbidity, quality of life and social and environmental circumstances' (\[[@CR11]\] p. 11). Also, when we screened systematic reviews with the term *primary care* in the title in the Cochrane library (<http://www.cochranelibrary.com/>), it became clear that primary care research is focused more on complex and process interventions than on single specific interventions such as a defined drug. The methodological problems with allocation concealment and attrition observed in completed German cluster-randomised trials fit very well with the problems described in analyses of such trials in general \[[@CR12]--[@CR15]\]. It seems to us that the protocols of the partly very large newly planned or ongoing trials try to take these problems and former experiences into account. We are not aware of any systematic analyses of effect sizes in general practice trials across conditions, but it seems plausible to us that, in the primary care setting with its multiple influence factors, intervention effects are often small. Yet, for some of the interventions tested in the trials reviewed by us, we wondered whether these were conceptually really promising and/or well implemented.

When interpreting our findings, it must be kept in mind that we searched and included only trials in which the first or last authors were affiliated with a German university GP department. Therefore, our results cannot be adopted for RCTs authored by GPs without such an affiliation. However, our check of the additional publications identified by Kortekaas et al. \[[@CR2]\] suggests the number of such studies is small. We excluded ten trials post hoc as they either were conducted when authors were working at other departments (and only written up later) or had no thematic relation to primary care whatsoever. We think these exclusions were necessary to allow for a judgement of the real RCT output of German academic GP departments relevant for their field. Due to limited resources, many working steps in this review were performed by a single author, with only some checks done by a second author. Therefore, some extraction or assessment errors might have gone undetected. The standardised mean differences calculated by us should be interpreted only as crude indicators of how large differences between groups were and should not be used for clinical decision-making.

Conclusions {#Sec12}
===========

Researchers in Germany's academic departments of general practice and family medicine increasingly perform and publish RCTs. However, without increased and sustained funding for research infrastructure and single trial projects, there will be little chance to catch up with leading countries such as the United Kingdom, the Netherlands, Scandinavian countries or the United States. We hope that our analysis will help to avoid some preventable shortcomings in future trials.

Additional files {#Sec13}
================

Additional file 1:References of included and excluded trials. (DOCX 32 kb)Additional file 2:Details of excluded studies. (DOCX 17 kb)
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